Resistance to proteasome inhibitors (PIs) and insufficient engagement of anti-tumor immunity are highlighted as principal obstacles to durable control of multiple myeloma (MM). The reported study frames therapeutic need along two axes: agents that remain active in PI-resistant disease and approaches that enhance tumor immunogenicity to recruit adaptive immune responses.
The authors identified anwulignan, a bioactive natural product, as a candidate compound with translational potential in MM. Anwulignan displayed potent cytotoxicity against MM cell lines, including models resistant to proteasome inhibition. The compound showed activity both as a single agent and when combined with established proteasome inhibitors.
In preclinical assays, anwulignan exhibited strong synergy with proteasome inhibitors in vitro, enhancing cytotoxic effects beyond monotherapy. These synergistic interactions translated to in vivo efficacy: in mouse MM models, combination treatment achieved more pronounced tumor suppression compared with single agents. The study reports that anwulignan treatment significantly suppressed tumor growth in these models while maintaining favorable tolerability and safety profiles in the experimental settings described.
Mechanistic investigations identified nucleophosmin 1 (NPM1) as a direct molecular target of anwulignan. The study links elevated NPM1 expression with poorer clinical outcomes in MM and demonstrates that inhibition of NPM1 by anwulignan induces cell-cycle arrest and apoptosis in MM cells. These tumor-intrinsic effects provide a direct mechanism for the cytotoxic activity observed in both PI-sensitive and PI-resistant settings.
Beyond apoptosis, anwulignan activated a caspase-1-dependent gasdermin D (GSDMD) cleavage cascade, triggering pyroptosis, a form of lytic programmed cell death. Activation of GSDMD-mediated pyroptosis produced features consistent with immunogenic cell death, thereby providing a mechanistic link between direct tumor killing and stimulation of anti-tumor immunity.
To assess the contribution of pyroptosis to therapeutic efficacy, the investigators used genetic silencing of GSDMD. Knockdown of GSDMD markedly impaired anwulignan-mediated tumor suppression in both in vitro assays and in vivo models. These loss-of-function experiments indicate that GSDMD-dependent pyroptosis is a critical effector mechanism for the anti-myeloma activity of anwulignan, not merely an epiphenomenon.
In immunocompetent syngeneic MM models, treatment with anwulignan increased the proportions of T cells in bone marrow and spleen. Anwulignan-treated, GSDMD-competent tumors showed superior tumor control compared with GSDMD-deficient tumors in these immune-competent settings. Together, these results support that pyroptosis induced by anwulignan promotes recruitment or expansion of anti-tumor T-cell populations and that immune engagement contributes substantively to in vivo efficacy.
The reported preclinical studies indicate that anwulignan produced significant tumor suppression in mouse models while maintaining a favorable tolerability and safety profile within the experiments conducted. The dual mechanism—direct targeting of tumor survival via NPM1 inhibition plus induction of pyroptosis-driven immunogenic cell death via caspase-1/GSDMD—supports a translational rationale for further development. The authors propose leveraging natural products such as anwulignan as immune-engaging strategies to target PI-resistant MM and improve therapeutic outcomes.
The summary and mechanistic conclusions presented here are based on the abstract and information available in the cited PubMed record. Detailed experimental parameters (for example, dosing regimens, specific cell lines, quantitative effect sizes, and full safety data) are not reported in the abstract and therefore are not described here. The study includes ethical approvals for animal experiments and human sample collection as noted in the source, and the authors declared no competing interests.